A Phase 3, Double-blind, Randomized Study of Zolbetuximab in Combination with Pembrolizumab and Chemotherapy (CAPOX or mFOLFOX6) in First-line Treatment of Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinom
Clinical Trial Grant
Awarded By
Astellas Pharma Global Development, Inc
Start Date
August 25, 2025
End Date
September 15, 2030
Awarded By
Astellas Pharma Global Development, Inc
Start Date
August 25, 2025
End Date
September 15, 2030